XIENCE 90 Study
Brief description of study
The objective of this trial is to evaluate safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with XIENCE.
Clinical Study Identifier: s18-01251
ClinicalTrials.gov Identifier: NCTs18-01251
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
